Use of positron emission tomography in anticancer drug development

Eric O. Aboagye; Patricia M. Price

doi:10.1023/A:1023521412787

Use of positron emission tomography in anticancer drug development

Eric O. Aboagye, Patricia M. Price

Research output: Contribution to journal › Article › peer-review

Abstract

Positron emission tomography (PET) is increasingly being used in anticancer drug development. The technique is applicable to studies of drug delivery, and where specific probes are available, to provide pharmacodynamic readouts noninvasively in patients. Mathematical modeling of the imaging data enhances the quality of information that is obtained from such studies. This section provides a review of the PET methodologies that have been used for the development of new cancer therapies. Other than imaging of radiolabeled drugs, PET modeling has found extensive application in studies with 2-[11C]thymidine, [18F]fluorodeoxyglucose, H215O, C15O, and receptor ligands.

Original language	English
Pages (from-to)	169-181
Number of pages	12
Journal	Investigational new drugs
Volume	21
Issue number	2
DOIs	https://doi.org/10.1023/A:1023521412787
Publication status	Published - May 2003

Keywords

Anticancer
Drug development
Modeling
Pharmacodynamics
Pharmacokinetics
Positron emission tomography

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1023/A:1023521412787

Cite this

@article{ec67fa4e94b04cbab4747ac5001e22a5,

title = "Use of positron emission tomography in anticancer drug development",

abstract = "Positron emission tomography (PET) is increasingly being used in anticancer drug development. The technique is applicable to studies of drug delivery, and where specific probes are available, to provide pharmacodynamic readouts noninvasively in patients. Mathematical modeling of the imaging data enhances the quality of information that is obtained from such studies. This section provides a review of the PET methodologies that have been used for the development of new cancer therapies. Other than imaging of radiolabeled drugs, PET modeling has found extensive application in studies with 2-[11C]thymidine, [18F]fluorodeoxyglucose, H215O, C15O, and receptor ligands.",

keywords = "Anticancer, Drug development, Modeling, Pharmacodynamics, Pharmacokinetics, Positron emission tomography",

author = "Aboagye, \{Eric O.\} and Price, \{Patricia M.\}",

year = "2003",

month = may,

doi = "10.1023/A:1023521412787",

language = "English",

volume = "21",

pages = "169--181",

journal = "Investigational new drugs",

issn = "1573-0646",

publisher = "Springer Nature",

number = "2",

}

TY - JOUR

T1 - Use of positron emission tomography in anticancer drug development

AU - Aboagye, Eric O.

AU - Price, Patricia M.

PY - 2003/5

Y1 - 2003/5

N2 - Positron emission tomography (PET) is increasingly being used in anticancer drug development. The technique is applicable to studies of drug delivery, and where specific probes are available, to provide pharmacodynamic readouts noninvasively in patients. Mathematical modeling of the imaging data enhances the quality of information that is obtained from such studies. This section provides a review of the PET methodologies that have been used for the development of new cancer therapies. Other than imaging of radiolabeled drugs, PET modeling has found extensive application in studies with 2-[11C]thymidine, [18F]fluorodeoxyglucose, H215O, C15O, and receptor ligands.

AB - Positron emission tomography (PET) is increasingly being used in anticancer drug development. The technique is applicable to studies of drug delivery, and where specific probes are available, to provide pharmacodynamic readouts noninvasively in patients. Mathematical modeling of the imaging data enhances the quality of information that is obtained from such studies. This section provides a review of the PET methodologies that have been used for the development of new cancer therapies. Other than imaging of radiolabeled drugs, PET modeling has found extensive application in studies with 2-[11C]thymidine, [18F]fluorodeoxyglucose, H215O, C15O, and receptor ligands.

KW - Anticancer

KW - Drug development

KW - Modeling

KW - Pharmacodynamics

KW - Pharmacokinetics

KW - Positron emission tomography

UR - https://www.scopus.com/pages/publications/0037812427

U2 - 10.1023/A:1023521412787

DO - 10.1023/A:1023521412787

M3 - Article

SN - 1573-0646

VL - 21

SP - 169

EP - 181

JO - Investigational new drugs

JF - Investigational new drugs

IS - 2

ER -

Use of positron emission tomography in anticancer drug development

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this